18 results on '"Qvit, Nir"'
Search Results
2. Engineering "Antimicrobial Peptides" and Other Peptides to Modulate Protein-Protein Interactions in Cancer.
- Author
-
Rubin SJS and Qvit N
- Subjects
- Antineoplastic Agents chemistry, Antineoplastic Agents metabolism, Humans, Neoplasm Proteins chemistry, Neoplasm Proteins metabolism, Neoplasms metabolism, Peptides chemistry, Peptides metabolism, Peptidomimetics chemistry, Peptidomimetics metabolism, Pore Forming Cytotoxic Proteins chemistry, Antineoplastic Agents pharmacology, Neoplasm Proteins antagonists & inhibitors, Neoplasms drug therapy, Peptides pharmacology, Peptidomimetics pharmacology, Pore Forming Cytotoxic Proteins metabolism, Protein Engineering
- Abstract
Antimicrobial peptides (AMPs) are a class of peptides found across a wide array of organisms that play key roles in host defense. AMPs induce selective death in target cells and orchestrate specific or nonspecific immune responses. Many AMPs exhibit native anticancer activity in addition to antibacterial activity, and others have been engineered as antineoplastic agents. We discuss the use of AMPs in the detection and treatment of cancer as well as mechanisms of AMP-induced cell death. We present key examples of cathelicidins and transferrins, which are major AMP families. Further, we discuss the critical roles of protein-protein interactions (PPIs) in cancer and how AMPs are well-suited to target PPIs based on their unique drug-like properties not exhibited by small molecules or antibodies. While peptides, including AMPs, can have limited stability and bioavailability, these issues can be overcome by peptide backbone modification or cyclization (e.g., stapling) and by the use of delivery systems such as cellpenetrating peptides (CPPs), respectively. We discuss approaches for optimizing drug properties of peptide and peptidomimetic leads (modified peptides), providing examples of promising techniques that may be applied to AMPs. These molecules represent an exciting resource as anticancer agents with unique therapeutic advantages that can target challenging mechanisms involving PPIs. Indeed, AMPs are suitable drug leads for further development of cancer therapeutics, and many studies to this end are underway., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2020
- Full Text
- View/download PDF
3. A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
- Author
-
Ferreira JCB, Campos JC, Qvit N, Qi X, Bozi LHM, Bechara LRG, Lima VM, Queliconi BB, Disatnik MH, Dourado PMM, Kowaltowski AJ, and Mochly-Rosen D
- Subjects
- Animals, GTP Phosphohydrolases metabolism, Gene Knockout Techniques, Heart Failure metabolism, Male, Mitochondrial Membranes metabolism, Myocardial Contraction, Myocardial Infarction metabolism, Myocardial Infarction pathology, Myocytes, Cardiac drug effects, Phosphorylation, RNA, Small Interfering, Rats, Wistar, Heart Failure drug therapy, Membrane Proteins antagonists & inhibitors, Mitochondrial Proteins antagonists & inhibitors, Peptides pharmacology, Protein Kinase C beta antagonists & inhibitors
- Abstract
We previously demonstrated that beta II protein kinase C (βIIPKC) activity is elevated in failing hearts and contributes to this pathology. Here we report that βIIPKC accumulates on the mitochondrial outer membrane and phosphorylates mitofusin 1 (Mfn1) at serine 86. Mfn1 phosphorylation results in partial loss of its GTPase activity and in a buildup of fragmented and dysfunctional mitochondria in heart failure. βIIPKC siRNA or a βIIPKC inhibitor mitigates mitochondrial fragmentation and cell death. We confirm that Mfn1-βIIPKC interaction alone is critical in inhibiting mitochondrial function and cardiac myocyte viability using SAMβA, a rationally-designed peptide that selectively antagonizes Mfn1-βIIPKC association. SAMβA treatment protects cultured neonatal and adult cardiac myocytes, but not Mfn1 knockout cells, from stress-induced death. Importantly, SAMβA treatment re-establishes mitochondrial morphology and function and improves cardiac contractility in rats with heart failure, suggesting that SAMβA may be a potential treatment for patients with heart failure.
- Published
- 2019
- Full Text
- View/download PDF
4. Interaction of mitochondrial fission factor with dynamin related protein 1 governs physiological mitochondrial function in vivo.
- Author
-
Kornfeld OS, Qvit N, Haileselassie B, Shamloo M, Bernardi P, and Mochly-Rosen D
- Subjects
- Adenosine Triphosphate metabolism, Animals, Cell Line, Tumor, Cells, Cultured, Cerebral Cortex cytology, Cerebral Cortex metabolism, Disease Models, Animal, Dynamins, GTP Phosphohydrolases chemistry, Humans, Huntington Disease metabolism, Membrane Proteins chemistry, Mice, Microtubule-Associated Proteins chemistry, Mitochondria drug effects, Mitochondrial Dynamics drug effects, Mitochondrial Proteins chemistry, Peptides chemistry, Peptides pharmacology, Protein Binding drug effects, GTP Phosphohydrolases metabolism, Huntington Disease chemically induced, Membrane Proteins metabolism, Microtubule-Associated Proteins metabolism, Mitochondria metabolism, Mitochondrial Proteins metabolism, Peptides administration & dosage
- Abstract
Mitochondria form a dynamic network governed by a balance between opposing fission and fusion processes. Because excessive mitochondrial fission correlates with numerous pathologies, including neurodegeneration, the mechanism governing fission has become an attractive therapeutic strategy. However, targeting fission is a double-edged sword as physiological fission is necessary for mitochondrial function. Fission is trigged by Drp1 anchoring to adaptors tethered to the outer mitochondrial membrane. We designed peptide P259 that distinguishes physiological from pathological fission by specifically inhibiting Drp1's interaction with the Mff adaptor. Treatment of cells with P259 elongated mitochondria and disrupted mitochondrial function and motility. Sustained in vivo treatment caused a decline in ATP levels and altered mitochondrial structure in the brain, resulting in behavioral deficits in wild-type mice and a shorter lifespan in a mouse model of Huntington's disease. Therefore, the Mff-Drp1 interaction is critical for physiological mitochondrial fission, motility, and function in vitro and in vivo. Tools, such as P259, that differentiate physiological from pathological fission will enable the examination of context-dependent roles of Drp1 and the suitability of mitochondrial fission as a target for drug development.
- Published
- 2018
- Full Text
- View/download PDF
5. Peptides and peptidomimetics as regulators of protein-protein interactions.
- Author
-
Cunningham AD, Qvit N, and Mochly-Rosen D
- Subjects
- Amino Acid Sequence, Animals, Humans, Molecular Targeted Therapy, Peptides chemistry, Peptidomimetics chemistry, Protein Binding, Protein Structure, Secondary, Drug Discovery methods, Peptides pharmacology, Peptidomimetics pharmacology
- Abstract
Protein-protein interactions are essential for almost all intracellular and extracellular biological processes. Regulation of protein-protein interactions is one strategy to regulate cell fate in a highly selective manner. Specifically, peptides are ideal candidates for inhibition of protein-protein interactions because they can mimic a protein surface to effectively compete for binding. Additionally, peptides are synthetically accessible and can be stabilized by chemical modifications. In this review, we survey screening and rational design methods for identifying peptides to inhibit protein-protein interactions, as well as methods for stabilizing peptides to effectively mimic protein surfaces. In addition, we discuss recent applications of peptides to regulate protein-protein interactions for both basic research and therapeutic purposes., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
6. Correcting mitochondrial fusion by manipulating mitofusin conformations.
- Author
-
Franco A, Kitsis RN, Fleischer JA, Gavathiotis E, Kornfeld OS, Gong G, Biris N, Benz A, Qvit N, Donnelly SK, Chen Y, Mennerick S, Hodgson L, Mochly-Rosen D, and Dorn GW II
- Subjects
- Animals, Cells, Cultured, Charcot-Marie-Tooth Disease genetics, Fibroblasts drug effects, Fibroblasts metabolism, Fibroblasts pathology, GTP Phosphohydrolases genetics, Mice, Mitochondria genetics, Mitochondria pathology, Mitochondrial Dynamics genetics, Models, Molecular, Neurons drug effects, Neurons metabolism, Neurons pathology, Peptides chemistry, Permeability, Protein Conformation drug effects, GTP Phosphohydrolases chemistry, GTP Phosphohydrolases metabolism, Mitochondria drug effects, Mitochondria metabolism, Mitochondrial Dynamics drug effects, Peptides pharmacology
- Abstract
Mitochondria are dynamic organelles that exchange contents and undergo remodelling during cyclic fusion and fission. Genetic mutations in MFN2 (the gene encoding mitofusin 2) interrupt mitochondrial fusion and cause the untreatable neurodegenerative condition Charcot-Marie-Tooth disease type 2A (CMT2A). It has not yet been possible to directly modulate mitochondrial fusion, in part because the structural basis of mitofusin function is not completely understood. Here we show that mitofusins adopt either a fusion-constrained or a fusion-permissive molecular conformation, directed by specific intramolecular binding interactions, and demonstrate that mitofusin-dependent mitochondrial fusion can be regulated in mouse cells by targeting these conformational transitions. On the basis of this model, we engineered a cell-permeant minipeptide to destabilize the fusion-constrained conformation of mitofusin and promote the fusion-permissive conformation, reversing mitochondrial abnormalities in cultured fibroblasts and neurons that harbour CMT2A-associated genetic defects. The relationship between the conformational plasticity of mitofusin 2 and mitochondrial dynamism reveals a central mechanism that regulates mitochondrial fusion, the manipulation of which can correct mitochondrial pathology triggered by defective or imbalanced mitochondrial dynamics.
- Published
- 2016
- Full Text
- View/download PDF
7. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Protein-Protein Interaction Inhibitor Reveals a Non-catalytic Role for GAPDH Oligomerization in Cell Death.
- Author
-
Qvit N, Joshi AU, Cunningham AD, Ferreira JC, and Mochly-Rosen D
- Subjects
- Animals, Cell Death drug effects, Cell Line, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) genetics, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) metabolism, Glycolysis physiology, Humans, Male, Mice, Phosphorylation drug effects, Phosphorylation physiology, Protein Kinase C-delta genetics, Protein Multimerization drug effects, Rats, Rats, Wistar, Zebrafish, Enzyme Inhibitors pharmacology, Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) antagonists & inhibitors, Glycolysis drug effects, Peptides pharmacology, Protein Kinase C-delta metabolism
- Abstract
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an important glycolytic enzyme, has a non-catalytic (thus a non-canonical) role in inducing mitochondrial elimination under oxidative stress. We recently demonstrated that phosphorylation of GAPDH by δ protein kinase C (δPKC) inhibits this GAPDH-dependent mitochondrial elimination. δPKC phosphorylation of GAPDH correlates with increased cell injury following oxidative stress, suggesting that inhibiting GAPDH phosphorylation should decrease cell injury. Using rational design, we identified pseudo-GAPDH (ψGAPDH) peptide, an inhibitor of δPKC-mediated GAPDH phosphorylation that does not inhibit the phosphorylation of other δPKC substrates. Unexpectedly, ψGAPDH decreased mitochondrial elimination and increased cardiac damage in an animal model of heart attack. Either treatment with ψGAPDH or direct phosphorylation of GAPDH by δPKC decreased GAPDH tetramerization, which corresponded to reduced GAPDH glycolytic activity in vitro and ex vivo Taken together, our study identified the potential mechanism by which oxidative stress inhibits the protective GAPDH-mediated elimination of damaged mitochondria. Our study also identified a pharmacological tool, ψGAPDH peptide, with interesting properties. ψGAPDH peptide is an inhibitor of the interaction between δPKC and GAPDH and of the resulting phosphorylation of GAPDH by δPKC. ψGAPDH peptide is also an inhibitor of GAPDH oligomerization and thus an inhibitor of GAPDH glycolytic activity. Finally, we found that ψGAPDH peptide is an inhibitor of the elimination of damaged mitochondria. We discuss how this unique property of increasing cell damage following oxidative stress suggests a potential use for ψGAPDH peptide-based therapy., (© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
8. Selective Phosphorylation Inhibitor of Delta Protein Kinase C-Pyruvate Dehydrogenase Kinase Protein-Protein Interactions: Application for Myocardial Injury in Vivo.
- Author
-
Qvit N, Disatnik MH, Sho E, and Mochly-Rosen D
- Subjects
- Animals, Male, Mice, Inbred BALB C, Molecular Docking Simulation, Myocardial Reperfusion Injury enzymology, Peptides chemistry, Peptides therapeutic use, Peptides toxicity, Phosphorylation, Protein Binding, Protein Kinase C-delta metabolism, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors toxicity, Protein Serine-Threonine Kinases metabolism, Pyruvate Dehydrogenase Acetyl-Transferring Kinase, Rats, Sprague-Dawley, Rats, Wistar, Recombinant Proteins, Substrate Specificity, Myocardial Reperfusion Injury drug therapy, Peptides chemical synthesis, Protein Kinase C-delta antagonists & inhibitors, Protein Kinase Inhibitors chemical synthesis, Protein Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Protein kinases regulate numerous cellular processes, including cell growth, metabolism, and cell death. Because the primary sequence and the three-dimensional structure of many kinases are highly similar, the development of selective inhibitors for only one kinase is challenging. Furthermore, many protein kinases are pleiotropic, mediating diverse and sometimes even opposing functions by phosphorylating multiple protein substrates. Here, we set out to develop an inhibitor of a selective protein kinase phosphorylation of only one of its substrates. Focusing on the pleiotropic delta protein kinase C (δPKC), we used a rational approach to identify a distal docking site on δPKC for its substrate, pyruvate dehydrogenase kinase (PDK). We reasoned that an inhibitor of PDK's docking should selectively inhibit the phosphorylation of only PDK without affecting phosphorylation of the other δPKC substrates. Our approach identified a selective inhibitor of PDK docking to δPKC with an in vitro Kd of ∼50 nM and reducing cardiac injury IC50 of ∼5 nM. This inhibitor, which did not affect the phosphorylation of other δPKC substrates even at 1 μM, demonstrated that PDK phosphorylation alone is critical for δPKC-mediated injury by heart attack. The approach we describe is likely applicable for the identification of other substrate-specific kinase inhibitors.
- Published
- 2016
- Full Text
- View/download PDF
9. Scaffold proteins LACK and TRACK as potential drug targets in kinetoplastid parasites: Development of inhibitors.
- Author
-
Qvit N, Schechtman D, Pena DA, Berti DA, Soares CO, Miao Q, Liang LA, Baron LA, Teh-Poot C, Martínez-Vega P, Ramirez-Sierra MJ, Churchill E, Cunningham AD, Malkovskiy AV, Federspiel NA, Gozzo FC, Torrecilhas AC, Manso Alves MJ, Jardim A, Momar N, Dumonteil E, and Mochly-Rosen D
- Subjects
- Amino Acid Sequence, Animals, Antigens, Protozoan chemistry, Drug Design, Leishmania chemistry, Leishmania genetics, Leishmaniasis drug therapy, Leishmaniasis parasitology, Mice, Parasitemia drug therapy, Peptides administration & dosage, Protozoan Proteins chemistry, Receptors for Activated C Kinase, Receptors, Cell Surface chemistry, Sequence Alignment, Trypanocidal Agents administration & dosage, Trypanocidal Agents chemistry, Trypanosoma genetics, Trypanosomiasis drug therapy, Trypanosomiasis parasitology, Leishmania drug effects, Peptides chemical synthesis, Peptides pharmacology, Protozoan Proteins antagonists & inhibitors, Receptors, Cell Surface antagonists & inhibitors, Trypanocidal Agents pharmacology, Trypanosoma drug effects
- Abstract
Parasitic diseases cause ∼ 500,000 deaths annually and remain a major challenge for therapeutic development. Using a rational design based approach, we developed peptide inhibitors with anti-parasitic activity that were derived from the sequences of parasite scaffold proteins LACK (Leishmania's receptor for activated C-kinase) and TRACK (Trypanosoma receptor for activated C-kinase). We hypothesized that sequences in LACK and TRACK that are conserved in the parasites, but not in the mammalian ortholog, RACK (Receptor for activated C-kinase), may be interaction sites for signaling proteins that are critical for the parasites' viability. One of these peptides exhibited leishmanicidal and trypanocidal activity in culture. Moreover, in infected mice, this peptide was also effective in reducing parasitemia and increasing survival without toxic effects. The identified peptide is a promising new anti-parasitic drug lead, as its unique features may limit toxicity and drug-resistance, thus overcoming central limitations of most anti-parasitic drugs.
- Published
- 2016
- Full Text
- View/download PDF
10. The Potential Use of Peptides in the Fight against Chagas Disease and Leishmaniasis.
- Author
-
Berhe, Hayelom, Kumar Cinthakunta Sridhar, Mahesh, Zerihun, Mulate, and Qvit, Nir
- Subjects
CHAGAS' disease ,LEISHMANIASIS ,NEGLECTED diseases ,PARASITIC diseases ,VECTOR-borne diseases ,THERAPEUTICS ,PEPTIDES - Abstract
Chagas disease and leishmaniasis are both neglected tropical diseases that affect millions of people around the world. Leishmaniasis is currently the second most widespread vector-borne parasitic disease after malaria. The World Health Organization records approximately 0.7–1 million newly diagnosed leishmaniasis cases each year, resulting in approximately 20,000–30,000 deaths. Also, 25 million people worldwide are at risk of Chagas disease and an estimated 6 million people are infected with Trypanosoma cruzi. Pentavalent antimonials, amphotericin B, miltefosine, paromomycin, and pentamidine are currently used to treat leishmaniasis. Also, nifurtimox and benznidazole are two drugs currently used to treat Chagas disease. These drugs are associated with toxicity problems such as nephrotoxicity and cardiotoxicity, in addition to resistance problems. As a result, the discovery of novel therapeutic agents has emerged as a top priority and a promising alternative. Overall, there is a need for new and effective treatments for Chagas disease and leishmaniasis, as the current drugs have significant limitations. Peptide-based drugs are attractive due to their high selectiveness, effectiveness, low toxicity, and ease of production. This paper reviews the potential use of peptides in the treatment of Chagas disease and leishmaniasis. Several studies have demonstrated that peptides are effective against Chagas disease and leishmaniasis, suggesting their use in drug therapy for these diseases. Overall, peptides have the potential to be effective therapeutic agents against Chagas disease and leishmaniasis, but more research is needed to fully investigate their potential. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. An Update on Protein Kinases as Therapeutic Targets—Part I: Protein Kinase C Activation and Its Role in Cancer and Cardiovascular Diseases.
- Author
-
Silnitsky, Shmuel, Rubin, Samuel J. S., Zerihun, Mulate, and Qvit, Nir
- Subjects
PROTEIN kinases ,DRUG target ,PROTEIN kinase inhibitors ,CARDIOVASCULAR diseases ,ALLOSTERIC regulation - Abstract
Protein kinases are one of the most significant drug targets in the human proteome, historically harnessed for the treatment of cancer, cardiovascular disease, and a growing number of other conditions, including autoimmune and inflammatory processes. Since the approval of the first kinase inhibitors in the late 1990s and early 2000s, the field has grown exponentially, comprising 98 approved therapeutics to date, 37 of which were approved between 2016 and 2021. While many of these small-molecule protein kinase inhibitors that interact orthosterically with the protein kinase ATP binding pocket have been massively successful for oncological indications, their poor selectively for protein kinase isozymes have limited them due to toxicities in their application to other disease spaces. Thus, recent attention has turned to the use of alternative allosteric binding mechanisms and improved drug platforms such as modified peptides to design protein kinase modulators with enhanced selectivity and other pharmacological properties. Herein we review the role of different protein kinase C (PKC) isoforms in cancer and cardiovascular disease, with particular attention to PKC-family inhibitors. We discuss translational examples and carefully consider the advantages and limitations of each compound (Part I). We also discuss the recent advances in the field of protein kinase modulators, leverage molecular docking to model inhibitor–kinase interactions, and propose mechanisms of action that will aid in the design of next-generation protein kinase modulators (Part II). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions.
- Author
-
Zerihun, Mulate, Rubin, Samuel J. S., Silnitsky, Shmuel, and Qvit, Nir
- Subjects
ALLOSTERIC proteins ,PROTEIN kinases ,PEPTIDES ,DRUG target ,SMALL molecules ,KINASES - Abstract
Human protein kinases are highly-sought-after drug targets, historically harnessed for treating cancer, cardiovascular disease, and an increasing number of autoimmune and inflammatory conditions. Most current treatments involve small molecule protein kinase inhibitors that interact orthosterically with the protein kinase ATP-binding pocket. As a result, these compounds are often poorly selective and highly toxic. Part I of this series reviews the role of PKC isoforms in various human diseases, featuring cancer and cardiovascular disease, as well as translational examples of PKC modulation applied to human health and disease. In the present Part II, we discuss alternative allosteric binding mechanisms for targeting PKC, as well as novel drug platforms, such as modified peptides. A major goal is to design protein kinase modulators with enhanced selectivity and improved pharmacological properties. To this end, we use molecular docking analysis to predict the mechanisms of action for inhibitor–kinase interactions that can facilitate the development of next-generation PKC modulators. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. De Novo Development of Mitochondria-Targeted Molecular Probes Targeting Pink1.
- Author
-
Ben-Uliel, Shulamit Fluss, Zoabi, Faten Habrat, Slavin, Moriya, Sibony-Benyamini, Hadas, Kalisman, Nir, and Qvit, Nir
- Subjects
MOLECULAR probes ,CYCLIC peptides ,CELL survival ,PEPTIDES ,FLUORESCENT dyes ,PEPTIDE mass fingerprinting - Abstract
Mitochondria play central roles in maintaining cellular metabolic homeostasis, cell survival and cell death, and generate most of the cell's energy. Mitochondria maintain their homeostasis by dynamic (fission and fusion) and quality control mechanisms, including mitophagy, the removal of damaged mitochondria that is mediated mainly by the Pink1/Parkin pathway. Pink1 is a serine/threonine kinase which regulates mitochondrial function, hitherto many molecular mechanisms underlying Pink1 activity in mitochondrial homeostasis and cell fate remain unknown. Peptides are vital biological mediators that demonstrate remarkable potency, selectivity, and low toxicity, yet they have two major limitations, low oral bioavailability and poor stability. Herein, we rationally designed a linear peptide that targets Pink1 and, using straightforward chemistry, we developed molecular probes with drug-like properties to further characterize Pink1. Initially, we conjugated a cell-penetrating peptide and a cross-linker to map Pink1's 3D structure and its interaction sites. Next, we conjugated a fluorescent dye for cell-imaging. Finally, we developed cyclic peptides with improved stability and binding affinity. Overall, we present a facile approach to converting a non-permeable linear peptide into a research tool possessing important properties for therapeutics. This is a general approach using straightforward chemistry that can be tailored for various applications by numerous laboratories. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. A Selective Inhibitor of Cardiac Troponin I Phosphorylation by Delta Protein Kinase C (δPKC) as a Treatment for Ischemia-Reperfusion Injury.
- Author
-
Qvit, Nir, Lin, Amanda J., Elezaby, Aly, Ostberg, Nicolai P., Campos, Juliane C., Ferreira, Julio C. B., and Mochly-Rosen, Daria
- Subjects
- *
TROPONIN I , *REPERFUSION injury , *MYOCARDIAL infarction , *MYOCARDIAL injury , *PEPTIDES , *PROTEIN kinase C - Abstract
Myocardial infarction is the leading cause of cardiovascular mortality, with myocardial injury occurring during ischemia and subsequent reperfusion (IR). We previously showed that the inhibition of protein kinase C delta (δPKC) with a pan-inhibitor (δV1-1) mitigates myocardial injury and improves mitochondrial function in animal models of IR, and in humans with acute myocardial infarction, when treated at the time of opening of the occluded blood vessel, at reperfusion. Cardiac troponin I (cTnI), a key sarcomeric protein in cardiomyocyte contraction, is phosphorylated by δPKC during reperfusion. Here, we describe a rationally-designed, selective, high-affinity, eight amino acid peptide that inhibits cTnI's interaction with, and phosphorylation by, δPKC (ψTnI), and prevents tissue injury in a Langendorff model of myocardial infarction, ex vivo. Unexpectedly, we also found that this treatment attenuates IR-induced mitochondrial dysfunction. These data suggest that δPKC phosphorylation of cTnI is critical in IR injury, and that a cTnI/δPKC interaction inhibitor should be considered as a therapeutic target to reduce cardiac injury after myocardial infarction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics.
- Author
-
Qvit, Nir, Kornfeld, Opher S., and Mochly ‐ Rosen, Daria
- Subjects
- *
PROTEIN kinases , *PHOSPHORYLATION , *CHEMICAL inhibitors , *PEPTIDES , *MYOCARDIAL infarction - Abstract
Most protein kinases phosphorylate multiple substrates, each of which induces different and sometimes opposing functions. Determining the role of phosphorylation of each substrate following a specific stimulus is challenging but is essential to elucidate the role of that substrate in the signaling event. Here we describe a rational approach to identify inhibitors of delta protein kinase C (δPKC), each inhibiting the phosphorylation of only one of δPKC′s substrates. δPKC regulates many signaling events and we hypothesized that a docking inhibitor of a given substrate to δPKC should selectively abrogate the phosphorylation of only that substrate, without affecting the phosphorylation of the other δPKC substrates. Here we report the development of selective inhibitors of three δPKC substrates (in vitro Kd≈3 n m); two greatly reduced ischemia-induced cardiac injury with an IC50 of ≈200 n m and the third had no effect, indicating that its respective substrate phosphorylation by δPKC has no role in the response to cardiac ischemia and reperfusion. The three inhibitors are highly specific; even at 1 μ m, the phosphorylation of other δPKC protein substrates was unaffected. The rationale we describe is likely applicable for the development of other substrate-specific inhibitors as well. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Rationally designed peptide regulators of protein kinase C
- Author
-
Churchill, Eric N., Qvit, Nir, and Mochly-Rosen, Daria
- Subjects
- *
PEPTIDES , *PROTEIN kinase C , *ISOENZYMES , *BLOOD circulation disorders - Abstract
Protein–protein interactions sequester enzymes close to their substrates. Protein kinase C (PKC) is one example of a ubiquitous signaling molecule with effects that are dependent upon localization. Short peptides derived from interaction sites between each PKC isozyme and its receptor for activated C kinase act as highly specific inhibitors and have become available as selective drugs in basic research and animal models of human diseases, such as myocardial infarction and hyperglycemia. Whereas the earlier inhibitory peptides are highly specific, we believe that peptides targeting additional interactions between PKC and selective substrates will generate even more selective tools that regulate different functions of individual isozymes. Here, we discuss the methodologies and applications for identifying selective regulators of PKC. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
17. A Laboratory Preparation of Aspartame Analogs Using Simultaneous Multiple Parallel Synthesis Methodology.
- Author
-
Qvit, Nir, Barda, Yaniv, Gilon, Chaim, and Shalev, Deborah E.
- Subjects
- *
ASPARTAME , *PEPTIDES , *CARBOXYLIC acids , *AMINO acids , *ORGANIC chemistry , *PROTEINS - Abstract
The article describes a laboratory preparation of aspartame analogs using simultaneous multiple parallel synthesis methodology. Many biological purposes require using numerous peptides that slightly differ in amino acid composition. To synthesize peptides the carboxylic acid group of the amino acid must be coupled to the amino group of previous amino acid while protecting any functional side chains that are present by using pre-protected residues. The synthesis and characterization of three dipeptide analogs of aspartame is demonstrated using the tea bag methodology.
- Published
- 2007
- Full Text
- View/download PDF
18. Berichtigung: Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics.
- Author
-
Qvit, Nir, Kornfeld, Opher S., and Mochly ‐ Rosen, Daria
- Subjects
- *
HEART , *PEPTIDES , *TETRAZOLIUM chloride - Abstract
A diagram is presented which explains the cardioprotective activity of peptides which are measured in whole hearts subjected to simulated myocardial infraction stained in triphenyltetrazolium chloride solution.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.